C4 Therapeutics reports Q3 2024 revenue $15.4M; net loss narrows to $0.35/share

C4 Therapeutics, Inc.

2023-Q1 EPS reported -$1.03 revenue$30,407,000

Revenue rose to $15.4M (up 39% YoY) driven by an $8M Biogen milestone and $2.9M from Betta license.
Net loss improved to $24.7M from $27.0M YoY; diluted EPS of -$0.35 vs -$0.55.
Cash, equivalents and marketable securities $284.4M at Sep 30; expected runway into 2027.
Cemsidomide Phase 1/2 trial enrolling; MM and NHL data to be presented at ASH Dec 2024.
Appointed Paige Mahaney as Chief Scientific Officer; delivered second Biogen development candidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.